(Q34585989)

3 August 2017

0 references

1 reference

title

Quetiapine: dose-response relationship in schizophrenia (English)

1 reference

3 August 2017

0 references

Anna Sparshatt

1

1 reference

3 August 2017

Sarah Jones

series ordinal

2

1 reference

3 August 2017

David Taylor

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2008

1 reference

3 August 2017

1 reference

3 August 2017

volume

22

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

49-68; discussion 69-72

1 reference

The positive and negative syndrome scale (PANSS) for schizophrenia

3 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200822010-00004

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200822010-00004

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200822010-00004

Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

12 December 2020

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

1 reference

12 December 2020

Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up

1 reference

12 December 2020

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

12 December 2020

High-dose quetiapine and photopsia

1 reference

12 December 2020

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

1 reference

12 December 2020

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action

1 reference

12 December 2020

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine

1 reference

12 December 2020

High degree of tolerability for monotherapy with high doses of quetiapine: a case report.

1 reference

12 December 2020

A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group

1 reference

12 December 2020

Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

12 December 2020

Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial

1 reference

12 December 2020

Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

1 reference

12 December 2020

Quetiapine dosage in bipolar disorder episodes and mixed states

1 reference

12 December 2020

Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

1 reference

12 December 2020

High-dose quetiapine in treatment refractory schizophrenia

1 reference

12 December 2020

Dose response and dose equivalence of antipsychotics

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

1 reference

12 December 2020

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

1 reference

12 December 2020

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

12 December 2020

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

1 reference

12 December 2020

Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.

1 reference

12 December 2020

Maintenance treatment for schizophrenia with quetiapine

1 reference

12 December 2020

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

12 December 2020

Managing acute exacerbations of schizophrenia: focus on quetiapine

1 reference

12 December 2020

Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine

1 reference

12 December 2020

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

1 reference

12 December 2020

Optimal dosing of atypical antipsychotics in adults: a review of the current evidence

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

1 reference

12 December 2020

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

1 reference

12 December 2020

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

1 reference

12 December 2020

First-episode schizophrenia: the importance of early intervention and subjective tolerability.

1 reference

12 December 2020

Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia

1 reference

12 December 2020

The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings

1 reference

12 December 2020

Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.

1 reference

12 December 2020

10.2165/00023210-200822010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1026664479

0 references

Fatcat ID

release_l3ufremnkfekvg6gvnythmeiiq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l3ufremnkfekvg6gvnythmeiiq

24 November 2022

mapped directly with Wikidata item

1 reference